



Newron Reports Additional Analyses of Ralfinamide Phase II Study
Further Confirmation of Efficacy of Ralfinamide in Neuropathic Pain

Milan, Italy – JULY 17, 2007 - Newron Pharmaceuticals S.p.A., (“Newron”, SWX: NWRN), a research and development company focused on novel CNS and pain therapies, today announces further results from the first placebo controlled, randomized treatment trial of ralfinamide in patients with various types of Neuropathic Pain. Previously announced results had indicated statistically significant superiority, $P=0.019$ (95% CI -14.9, -1.4), of ralfinamide compared with placebo on the patient rated Visual Analog Scale (VAS) – a measure of the severity of pain, while showing good tolerability at the doses tested. Additional analyses have revealed that ralfinamide treatment is associated with multiple statistically significant differences and clinically relevant benefit over placebo as judged by:

- Responder analysis using multiple definitions of the magnitude of pain relief as judged on the VAS: overall $P<0.05$
- Significant improvement in the mean ratings of the patient rated Daily Pain Diary: $P=0.003$ (95% CI -1.5, -0.3)
- Significant improvement in the quality of sleep as judged by the patient: $P=0.002$ (95% CI -1.5, -0.4)
- Significant improvement in daily activities: $P=0.033$ (95% CI -1.4, -0.1)

(For study design and additional detail please refer to press release dd July 2, 2007).

Ravi Anand, Chief Medical Officer of Newron, commented: “These additional results are extremely encouraging, as they indicate that the beneficial effects of ralfinamide extend not only to pain relief, but also to daily activities as well as quality of sleep. These combined effects will improve the quality of life for patients. Substantial benefit over placebo was noted for many types of neuropathic pain.

Overall, the promising efficacy results together with the good tolerability observed in this study suggest that ralfinamide may provide a new standard of care for patients with neuropathic pain.”

About ralfinamide

Ralfinamide is a unique New Chemical Entity that combines use and frequency dependent inhibition of sodium channels present on sensory neurons and blockade of calcium ion flow, believed to be implicated in the pathogenesis of neuropathic pain.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System, particularly Parkinson’s disease (PD), and pain. Newron is undertaking phase III trials with safinamide, a unique molecule with multiple mechanisms of action, for the treatment of PD in conjunction with its partner, Merck Serono, which has the rights to develop the compound in PD, Alzheimer’s disease, other cognitive disorders and Restless Legs Syndrome. Recent results of a six-month phase III trial of safinamide in PD demonstrated its benefit in motor symptoms and activities of daily living, as well as its improvement in cognitive function and good tolerability. Newron and Merck Serono are planning to expand the development of safinamide to exploit its potential in Alzheimer’s disease. Phase II trials with safinamide in Restless Legs Syndrome have shown promising results. Newron is also conducting a phase II programme with ralfinamide for the treatment of neuropathic pain. Phase II data lately reported suggest that ralfinamide is effective in the the treatment of this condition. The drug has potential benefit in inflammatory pain, as well. Newron’s clinical pipeline is supported by a portfolio of early-stage proprietary compounds generated by its ion channel drug discovery platform. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol NWRN.

For more information, contact:

Media	Investors and analysts
Italy Luca Benatti - CEO Phone: +39 02 6103 4 626	Stefan Weber - CFO Phone: +39 02 6103 46 30
UK/Global media Julia Phillips Financial Dynamics Phone: +44 (0) 20 7269 7187	

Switzerland	
--------------------	--

Martin Meier-Pfister	
----------------------	--

The Investor Relations Firm AG	
--------------------------------	--

Phone: +41 43 244 81 40	
-------------------------	--

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Newron undertakes no obligation to publicly update or revise any forward-looking statements.